Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$8.51 USD
+0.24 (2.90%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $8.50 -0.01 (-0.12%) 6:06 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
SRRK 8.51 +0.24(2.90%)
Will SRRK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRRK
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
SRRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
Other News for SRRK
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock: Enrollment complete in Phase 2 trial of apitegromab for obesity
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
Scholar Rock appoints Beth Shafer, Ph.D. Chief Business Officer